Open-label, multicenter study of self-administered icatibant for attacks of hereditary angioedema

Allergy: European Journal of Allergy and Clinical Immunology

Volumn 69, Issue 3, 2014, Pages 305-314

  Aberer, W ^a   Maurer, M ^b   Reshef, A ^c   Longhurst, H ^d   Kivity, S ^e   Bygum, A ^f   Caballero, T ^g   Bloom, B ^h   Nair, N ⁱ   Malbran A ^j  

^a MEDICAL UNIVERSITY OF GRAZ   (Austria)

^b CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^c SHEBA MEDICAL CENTER   (Israel)

^d ROYAL LONDON HOSPITAL   (United Kingdom)

^e TEL AVIV SOURASKY MEDICAL CENTER   (Israel)

^f ODENSE UNIVERSITY HOSPITAL   (Denmark)

^g HOSPITAL UNIVERSITARIO LA PAZ IDIPAZ   (Spain)

^h Department of Clinical Development ^*  (United States)

ⁱ Global Clinical Research   (United States)

^j HOSPITAL BRITÁNICO DE BUENOS AIRES   (Argentina)

more..

Author keywords

bradykinin; C1 esterase inhibitor deficiency; hereditary angioedema; icatibant; self administration

Indexed keywords

ADULT; ANGIOEDEMAS, HEREDITARY; BRADYKININ; DISEASE PROGRESSION; FEMALE; HEREDITARY ANGIOEDEMA TYPES I AND II; HUMANS; MALE; MIDDLE AGED; PATIENT SATISFACTION; RECEPTORS, BRADYKININ; RECURRENCE; RISK FACTORS; SELF ADMINISTRATION; TREATMENT OUTCOME;

EID: 84894235031     PISSN: 01054538     EISSN: 13989995     Source Type: Journal    
DOI: 10.1111/all.12303     Document Type: Article

References (27)

1. Bowen T, Cicardi M, Farkas H, Bork K, Longhurst HJ, Zuraw B, et al. International consensus algorithm for the diagnosis, therapy and management of hereditary angioedema. Allergy Asthma Clin Immunol 2010; 6: 24.
2. Frank MM,. Hereditary angioedema. J Allergy Clin Immunol 2008; 121 (Suppl 2): S398-S401.
3. Longhurst H, Cicardi M,. Hereditary angio-oedema. Lancet 2012; 379: 474-481.
4. Cugno M, Nussberger J, Cicardi M, Agostoni A,. Bradykinin and the pathophysiology of angioedema. Int Immunopharmacol 2003; 3: 311-317.
5. Nussberger J, Cugno M, Amstutz C, Cicardi M, Pellacani A, Agostoni A,. Plasma bradykinin in angio-oedema. Lancet 1998; 351: 1693-1697.
6. Cicardi M, Bork K, Caballero T, Craig T, Li HH, Longhurst H, et al.: on behalf of HAWK* (Hereditary Angioedema International Working Group). Evidence-based recommendations for the therapeutic management of angioedema owing to hereditary C1 inhibitor deficiency: consensus report of an International Working Group. Allergy 2012; 67: 147-157.
7. Zuraw BL,. Clinical practice. Hereditary angioedema. N Engl J Med 2008; 359: 1027-1036.
8. Zilberberg MD, Nathanson BH, Jacobsen T, Tillotson G,. Descriptive epidemiology of hereditary angioedema hospitalizations in the United States, 2004-2007. Allergy Asthma Proc 2011; 32: 248-254.
9. Wilson DA, Bork K, Shea EP, Rentz AM, Blaustein MB, Pullman WE,. Economic costs associated with acute attacks and long-term management of hereditary angioedema. Ann Allergy Asthma Immunol 2010; 104: 314-320.
10. Toscani M, Riedl M,. Meeting the challenges and burdens associated with hereditary angioedema. Manag Care 2011; 20: 44-51.
11. Zanichelli A, Vacchini R, Badini M, Penna V, Cicardi M,. Standard care impact on angioedema because of hereditary C1 inhibitor deficiency: a 21-month prospective study in a cohort of 103 patients. Allergy 2011; 66: 192-196.
12. Longhurst HJ, Farkas H, Craig T, Aygören-Pürsün E, Bethune C, Bjorkander J, et al. HAE international home therapy consensus document. Allergy Asthma Clin Immunol 2010; 6: 22.
13. Cicardi M, Banerji A, Bracho F, Malbrán A, Rosenkranz B, Riedl M, et al. Icatibant, a new bradykinin-receptor antagonist, in hereditary angioedema. N Engl J Med 2010; 363: 532-541.
14. Lumry WR, Li HH, Levy RJ, Potter PC, Farkas H, Moldovan D, et al. Randomized placebo-controlled trial of the bradykinin B2 receptor antagonist icatibant for the treatment of acute attacks of hereditary angioedema: the FAST-3 trial. Ann Allergy Asthma Immunol 2011; 107: 529-537.
15. Farkas H, Csuka D, Zotter Z, Varga L, Böröcz Z, Temesszentandrási G, et al. Home treatment of hereditary angioedema with icatibant administered by health care professionals. J Allergy Clin Immunol 2012; 129: 851-852.
16. Boccon-Gibod I, Bouillet L,. Safety and efficacy of icatibant self-administration for acute hereditary angioedema. Clin Exp Immunol 2012; 168: 303-307.
17. The Criteria Committee of the New York Heart Association. Nomenclature and Criteria for Diagnosis of Diseases of the Heart and Great Vessels. 9th edn. Boston, MA: Little, Brown & Co, 1994: 253-256.
18. Atkinson MJ, Sinha A, Hass SL, Colman SS, Kumar RN, Brod M, et al. Validation of a general measure of treatment satisfaction, the Treatment Satisfaction Questionnaire for Medication (TSQM), using a national panel study of chronic disease. Health Qual Life Outcomes 2004; 2: 12.
19. Craig TJ, Wasserman RL, Levy RJ, Bewtra AK, Schneider L, Packer F, et al. Prospective study of rapid relief provided by C1 esterase inhibitor in emergency treatment of acute laryngeal attacks in hereditary angioedema. J Clin Immunol 2010; 30: 823-829.
20. Sheffer AL, Campion M, Levy RJ, Li HH, Horn PT, Pullman WE,. Ecallantide (DX-88) for acute hereditary angioedema attacks: integrated analysis of 2 double-blind, phase 3 studies. J Allergy Clin Immunol 2011; 128: 153-159.
21. Zuraw BL, Busse PJ, White M, Jacobs J, Lumry W, Baker J, et al. Nanofiltered C1 inhibitor concentrate for treatment of hereditary angioedema. N Engl J Med 2010; 363: 513-522.
22. Zuraw B, Cicardi M, Levy RJ, Nuijens JH, Relan A, Visscher S, et al. Recombinant human C1-inhibitor for the treatment of acute angioedema attacks in patients with hereditary angioedema. J Allergy Clin Immunol 2010; 126: 821-827.
23. McCauley TG, Kramer WG, Fahy L, Bloom BJ,. Clinical pharmacokinetics, pharmacodynamics and duration of action of icatibant. Am Soc Clin Pharmacol Ther 113th Annual meeting 2012; 91 (Suppl 1): S121.
24. Bygum A, Andersen KE, Mikkelsen CS,. Self-administration of intravenous C1-inhibitor therapy for hereditary angioedema and associated quality of life benefits. Eur J Dermatol 2009; 19: 147-151.
25. Levi M, Choi G, Picavet C, Hack CE,. Self-administration of C1-inhibitor concentrate in patients with hereditary or acquired angioedema caused by C1-inhibitor deficiency. J Allergy Clin Immunol 2006; 117: 904-908.
26. Weller K, Groffik A, Magerl M, Tohme N, Martus P, Krause K, et al. Development and validation of the angioedema Quality of Life Questionnaire (AE-QoL). Allergy 2012; 67: 1289-1298.
27. Weller K, Groffik A, Magerl M, Tohme N, Martus P, Krause K, et al. Development, validation and initial results of the Angioedema Activity Score. Allergy 2013; 68: 1185-1192.